Stay updated on ASP1517 Oral Dosing in Anemia: Clinical Trial
Sign up to get notified when there's something new on the ASP1517 Oral Dosing in Anemia: Clinical Trial page.

Latest updates to the ASP1517 Oral Dosing in Anemia: Clinical Trial page
- CheckyesterdayChange DetectedThe study record now presents detailed information about the completed Phase 3 roxadustat trial for anemia in people with non-dialysis chronic kidney disease. It also describes Astellas’ plan and criteria for sharing anonymized participant data and supporting study documents.SummaryDifference65%

- Check8 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check15 days agoChange DetectedA banner announces updates to NIH websites and says federal agencies are using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) during the transition.SummaryDifference1%

- Check22 days agoChange DetectedThe footer revision changed from v3.7.1 to v3.7.2, while the page continued to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check29 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check50 days agoChange DetectedThe page now renders as a 403 Forbidden error, replacing the usual study content with an access-restricted message. The visible elements include the error header, a Home button, and the standard footer, indicating blocked access rather than a data update.SummaryDifference18%

Stay in the know with updates to ASP1517 Oral Dosing in Anemia: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ASP1517 Oral Dosing in Anemia: Clinical Trial page.